Oral anticoagulation in atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Atrial fibrillation (AF) impacts millions, with stroke risk varying by individual factors.
• Warfarin, a vitamin K antagonist, has been the standard for AF stroke prevention but presents management challenges.
• Recent FDA approvals introduced novel oral anticoagulants (NOACs) as alternatives.

Purpose of the Study:

• To review landmark trials (RE-LY, ROCKET-AF, ARISTOTLE) comparing NOACs to warfarin for stroke prevention in AF.
• To discuss practical aspects of NOAC use, including cost, reversal, interactions, and perioperative management.

Main Methods:

• Systematic review and meta-analysis of data from three major randomized controlled trials.
• Comparative analysis of efficacy (stroke/systemic embolism reduction) and safety (bleeding events, mortality).

Main Results:

• Dabigatran 150 mg BID showed a 34% reduction in stroke/systemic embolism versus warfarin with similar major bleeding rates.
• Rivaroxaban demonstrated non-inferiority to warfarin for stroke/systemic embolism and major bleeding.
• Apixaban achieved a 21% relative risk reduction in stroke/systemic embolism and a 31% reduction in major bleeding, alongside a mortality benefit.
• All three NOACs significantly reduced intracranial hemorrhage rates compared to warfarin.
• Apixaban demonstrated superiority in reducing strokes, major bleeding, and mortality.

Conclusions:

• NOACs (Dabigatran, Rivaroxaban, Apixaban) are effective alternatives to warfarin for stroke prevention in non-valvular AF.
• Apixaban exhibits superior efficacy and safety outcomes, including a mortality benefit, compared to warfarin.
• NOACs offer potential cost reductions and improved patient management, though specific considerations for each agent remain.